HCPCS Level II · Drugs administered other than oral method
J9300Injection, gemtuzumab ozogamicin, 5 mg
Terminated 12/31/2017
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J9300
J9300 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, gemtuzumab ozogamicin, 5 mg.
It was added to HCPCS effective 01/01/2002, and its current record took effect 01/01/2018.
It was terminated on 12/31/2017 and can't be billed for later dates of service.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Gemtuzumab ozogamicin inj
- Date added
- 01/01/2002
- Action effective
- 01/01/2018
- Termination date
- 12/31/2017
- BETOS
- O1D
Related J93xx codes
- J9301Injection, obinutuzumab, 10 mg
- J9302Injection, ofatumumab, 10 mg
- J9303Injection, panitumumab, 10 mg
- J9304Injection, pemetrexed (pemfexy), 10 mg
- J9305Injection, pemetrexed, not otherwise specified, 10 mg
- J9306Injection, pertuzumab, 1 mg
- J9307Injection, pralatrexate, 1 mg
- J9308Injection, ramucirumab, 5 mg
- J9309Injection, polatuzumab vedotin-piiq, 1 mg
- J9311Injection, rituximab 10 mg and hyaluronidase
- J9312Injection, rituximab, 10 mg
- J9313Injection, moxetumomab pasudotox-tdfk, 0.01 mg
Common questions about J9300
Is HCPCS J9300 still valid?
- No. J9300 was terminated on 12/31/2017.
Does Medicare cover J9300?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.